XML 26 R17.htm IDEA: XBRL DOCUMENT v3.22.1
NOTE 12 - SEGMENT INFORMATION
9 Months Ended
Jan. 31, 2022
Notes  
NOTE 12 - SEGMENT INFORMATION

NOTE 12 - SEGMENT INFORMATION

 

The following information is presented in accordance with ASC Topic 280, "Segment Reporting", for the three and nine months ended January 31, 2022 and 2021; we accounted for two reportable business segments - (1) natural sweetener (stevioside), and (2) corporate and other pharmaceutical. Our reportable segments are strategic business units that offer different products and are managed separately based on the fundamental differences in their operations. Condensed financial information with respect to these reportable business segments for the three and nine months ended January 31, 2022 and 2021 is as follows: 

 

 

Three Months Ended January 31,

Nine Months Ended January 31,

  

2022

2021

2022

 2021

Revenues:

 

 

 

 

Stevioside - third party

$10,890,274  

$4,125,587  

$27,053,429  

$13,146,390  

Stevioside - related party

 

2,756,224  

 

5,010,742  

Total Stevioside

10,890,274  

6,881,811  

27,053,429  

18,157,132  

 

 

 

 

 

Corporate and other – third party

107,991  

104,866  

321,420  

303,067  

Corporate and other – related party

 

 

 

 

Total Corporate and other

107,991  

104,866  

321,420  

303,067  

Total segment and consolidated revenues

$10,998,265  

$6,986,677  

$27,374,849  

$18,460,199  

Interest expense:

 

 

 

 

Stevioside

$(144,182) 

$(61,727) 

$(334,787) 

$(192,852) 

Corporate and other

 

 

 

 

Total segment and consolidated interest expense

$(144,182) 

$(61,727) 

$(334,787) 

$(192,852) 

Depreciation and amortization:

 

 

 

 

Stevioside

$332,025  

$289,361  

$955,906  

$809,215  

Corporate and other

52,642  

60,174  

165,584  

166,880  

Total segment and consolidated depreciation and amortization

$384,667  

$349,535  

$1,121,490  

$976,095  

Income (loss) from operations before income taxes:

 

 

 

 

Stevioside

$(1,615,128) 

$(1,808,789) 

$(4,369,070) 

$(3,578,716) 

Corporate and other

54,635  

47,943  

165,687  

103,592  

Total loss from continuing operations before income taxes

$(1,560,493) 

$(1,760,846) 

$(4,203,383) 

$(3,475,124) 

 

 

  

January 31,

2022

April 30,

2021

Segment property and equipment:

 

 

  Stevioside

$6,580,695 

$7,354,695 

  Corporate and other

1,726,278 

1,862,420 

    Total property and equipment

$8,306,973 

$9,217,115